Dotter Inc. acquired the exclusive domestic rights to EluNIR™ through a recent contract with Israeli company Medinol.
EluNIR™ is scheduled to be marketed in Korea early next year through Dotter.
By Connecting Technology and People, We Save Lives and Make Life Better for Humanity
As a company established by a combination of cardiovascular specialists and the best experts in Korea and the world in the field of optical coherence tomography (OCT), we are designing and producing sophisticated biodegradable stents (BRS) that are 1/3 the thickness of competitors. In addition, we are mainly developing next-generation OCT equipment, which is optical imaging equipment that can create a synergistic effect for stent insertion.